Literature DB >> 30226476

Vismodegib treatment in a HIV positive patient on antiretroviral therapy.

Massimiliano Scalvenzi1, Alessia Villani1, Caterina Mazzella1, Milena Cappello1, Gaia De Fata Salvatores1, Claudia Costa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30226476     DOI： 10.4103/ijdvl.IJDVL_92_18

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  3 in total

1.  Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.

Authors:  Massimiliano Scalvenzi; Milena Cappello; Claudia Costa; Gabriella Fabbrocini; Mariaantonietta Luciano; Alessia Villani
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-02

Review 2.  Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma.

Authors:  Alessia Villani; Gabriella Fabbrocini; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-15

3.  Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).

Authors:  Alessia Villani; Matteo Megna; Gabriella Fabbrocini; Milena Cappello; Maria Antonietta Luciano; Claudia Costa; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2019-09-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.